IDEAYA Biosciences, Inc. (IDYA) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à South San Francisco, CA, United States. Le PDG actuel est Yujiro S. Hata.
IDYA a date d'introduction en bourse 2019-05-23, 131 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $2.84B.
IDEAYA Biosciences is a precision medicine oncology company focused on synthetic lethality, developing targeted cancer therapeutics for patient populations selected through molecular diagnostics. The company's lead candidates include IDE397, a methionine adenosyltransferase 2a inhibitor in Phase I trials for solid tumors with MTAP deletions, and IDE196, a protein kinase C inhibitor in Phase I/II trials for cancers with GNAQ or GNA11 mutations. Its preclinical pipeline targets multiple synthetic lethality pathways, including PARG inhibitors, Pol Theta inhibitors for BRCA-deficient tumors, and WRN inhibitors for microsatellite instability-high cancers. The company collaborates with leading organizations including Cancer Research UK, the University of Manchester, Pfizer, and GlaxoSmithKline. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA is advancing precision oncology through genetically-defined patient selection and targeted drug development.
